1
|
Schwinghamer K, Line S, Tesar DB, Miller DW, Sreedhara A, Siahaan TJ. Selective Uptake of Macromolecules to the Brain in Microfluidics and Animal Models Using the HAVN1 Peptide as a Blood-Brain Barrier Modulator. Mol Pharm 2024; 21:1639-1652. [PMID: 38395041 PMCID: PMC10984760 DOI: 10.1021/acs.molpharmaceut.3c00775] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/25/2024]
Abstract
Monoclonal antibodies (mAbs) possess favorable pharmacokinetic properties, high binding specificity and affinity, and minimal off-target effects, making them promising therapeutic agents for central nervous system (CNS) disorders. However, their development as effective therapeutic and diagnostic agents for brain disorders is hindered by their limited ability to efficiently penetrate the blood-brain barrier (BBB). Therefore, it is crucial to develop efficient delivery methods that enhance the penetration of antibodies into the brain. Previous studies have demonstrated the potential of cadherin-derived peptides (i.e., ADTC5, HAVN1 peptides) as BBB modulators (BBBMs) to increase paracellular porosities for penetration of molecules across the BBB. Here, we test the effectiveness of the leading BBBM peptide, HAVN1 (Cyclo(1,6)SHAVSS), in enhancing the permeation of various monoclonal antibodies through the BBB using both in vitro and in vivo systems. In vitro, HAVN1 has been shown to increase the permeability of fluorescently labeled macromolecules, such as a 70 kDa dextran, 50 kDa Fab1, and 150 kDa mAb1, by 4- to 9-fold in a three-dimensional blood-brain barrier (3D-BBB) microfluidics model using a human BBB endothelial cell line (i.e., hCMEC/D3). HAVN1 was selective in modulating the BBB endothelial cell, compared to the pulmonary vascular endothelial (PVE) cell barrier. Co-administration of HAVN1 significantly improved brain depositions of mAb1, mAb2, and Fab1 in C57BL/6 mice after 15 min in the systemic circulation. Furthermore, HAVN1 still significantly enhanced brain deposition of mAb2 when it was administered 24 h after the administration of the mAb. Lastly, we observed that multiple doses of HAVN1 may have a cumulative effect on the brain deposition of mAb2 within a 24-h period. These findings offer promising insights into optimizing HAVN1 and mAb dosing regimens to control or modulate mAb brain deposition for achieving desired mAb dose in the brain to provide its therapeutic effects.
Collapse
Affiliation(s)
- Kelly Schwinghamer
- Department of Pharmaceutical Chemistry, The University of Kansas, 2093 Constant Ave., Lawrence, KS 66047, USA
| | - Stacey Line
- Department of Pharmacology and Therapeutics, University of Manitoba, 753 McDermot Avenue Winnipeg, MB, R3E 0T6, Canada
| | - Devin B. Tesar
- Department of Pharmaceutical Development, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | - Donald W. Miller
- Department of Pharmacology and Therapeutics, University of Manitoba, 753 McDermot Avenue Winnipeg, MB, R3E 0T6, Canada
| | - Alavattam Sreedhara
- Department of Pharmaceutical Development, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | - Teruna J. Siahaan
- Department of Pharmaceutical Chemistry, The University of Kansas, 2093 Constant Ave., Lawrence, KS 66047, USA
| |
Collapse
|
2
|
Sánchez-Robles EM, Girón R, Paniagua N, Rodríguez-Rivera C, Pascual D, Goicoechea C. Monoclonal Antibodies for Chronic Pain Treatment: Present and Future. Int J Mol Sci 2021; 22:ijms221910325. [PMID: 34638667 PMCID: PMC8508878 DOI: 10.3390/ijms221910325] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2021] [Revised: 09/22/2021] [Accepted: 09/22/2021] [Indexed: 12/20/2022] Open
Abstract
Chronic pain remains a major problem worldwide, despite the availability of various non-pharmacological and pharmacological treatment options. Therefore, new analgesics with novel mechanisms of action are needed. Monoclonal antibodies (mAbs) are directed against specific, targeted molecules involved in pain signaling and processing pathways that look to be very effective and promising as a novel therapy in pain management. Thus, there are mAbs against tumor necrosis factor (TNF), nerve growth factor (NGF), calcitonin gene-related peptide (CGRP), or interleukin-6 (IL-6), among others, which are already recommended in the treatment of chronic pain conditions such as osteoarthritis, chronic lower back pain, migraine, or rheumatoid arthritis that are under preclinical research. This narrative review summarizes the preclinical and clinical evidence supporting the use of these agents in the treatment of chronic pain.
Collapse
|
3
|
Pan C, Schoppe O, Parra-Damas A, Cai R, Todorov MI, Gondi G, von Neubeck B, Böğürcü-Seidel N, Seidel S, Sleiman K, Veltkamp C, Förstera B, Mai H, Rong Z, Trompak O, Ghasemigharagoz A, Reimer MA, Cuesta AM, Coronel J, Jeremias I, Saur D, Acker-Palmer A, Acker T, Garvalov BK, Menze B, Zeidler R, Ertürk A. Deep Learning Reveals Cancer Metastasis and Therapeutic Antibody Targeting in the Entire Body. Cell 2020; 179:1661-1676.e19. [PMID: 31835038 DOI: 10.1016/j.cell.2019.11.013] [Citation(s) in RCA: 112] [Impact Index Per Article: 28.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2019] [Revised: 10/02/2019] [Accepted: 11/12/2019] [Indexed: 12/20/2022]
Abstract
Reliable detection of disseminated tumor cells and of the biodistribution of tumor-targeting therapeutic antibodies within the entire body has long been needed to better understand and treat cancer metastasis. Here, we developed an integrated pipeline for automated quantification of cancer metastases and therapeutic antibody targeting, named DeepMACT. First, we enhanced the fluorescent signal of cancer cells more than 100-fold by applying the vDISCO method to image metastasis in transparent mice. Second, we developed deep learning algorithms for automated quantification of metastases with an accuracy matching human expert manual annotation. Deep learning-based quantification in 5 different metastatic cancer models including breast, lung, and pancreatic cancer with distinct organotropisms allowed us to systematically analyze features such as size, shape, spatial distribution, and the degree to which metastases are targeted by a therapeutic monoclonal antibody in entire mice. DeepMACT can thus considerably improve the discovery of effective antibody-based therapeutics at the pre-clinical stage. VIDEO ABSTRACT.
Collapse
Affiliation(s)
- Chenchen Pan
- Institute for Tissue Engineering and Regenerative Medicine (iTERM), Helmholtz Zentrum München, 85764 Neuherberg, Germany; Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig Maximilian University of Munich (LMU), 81377 Munich, Germany
| | - Oliver Schoppe
- Department of Informatics, Technical University of Munich, 85748 Munich, Germany; Center for Translational Cancer Research (TranslaTUM), Klinikum rechts der Isar, Technical University of Munich, 81675 Munich, Germany
| | - Arnaldo Parra-Damas
- Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig Maximilian University of Munich (LMU), 81377 Munich, Germany
| | - Ruiyao Cai
- Institute for Tissue Engineering and Regenerative Medicine (iTERM), Helmholtz Zentrum München, 85764 Neuherberg, Germany; Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig Maximilian University of Munich (LMU), 81377 Munich, Germany
| | - Mihail Ivilinov Todorov
- Institute for Tissue Engineering and Regenerative Medicine (iTERM), Helmholtz Zentrum München, 85764 Neuherberg, Germany; Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig Maximilian University of Munich (LMU), 81377 Munich, Germany; Graduate School of Systemic Neurosciences (GSN), 82152 Munich, Germany
| | - Gabor Gondi
- Research Unit Gene Vectors, Helmholtz Zentrum München, 81377 Munich, Germany
| | - Bettina von Neubeck
- Research Unit Gene Vectors, Helmholtz Zentrum München, 81377 Munich, Germany
| | | | - Sascha Seidel
- Institute of Cell Biology and Neuroscience and Buchmann Institute for Molecular Life Sciences (BMLS), University of Frankfurt, 60323 Frankfurt, Germany
| | - Katia Sleiman
- Center for Translational Cancer Research (TranslaTUM), Klinikum rechts der Isar, Technical University of Munich, 81675 Munich, Germany; Division of Translational Cancer Research, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; German Cancer Consortium (DKTK), Partner Site Munich, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany
| | - Christian Veltkamp
- Center for Translational Cancer Research (TranslaTUM), Klinikum rechts der Isar, Technical University of Munich, 81675 Munich, Germany; Division of Translational Cancer Research, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; German Cancer Consortium (DKTK), Partner Site Munich, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany
| | - Benjamin Förstera
- Institute for Tissue Engineering and Regenerative Medicine (iTERM), Helmholtz Zentrum München, 85764 Neuherberg, Germany; Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig Maximilian University of Munich (LMU), 81377 Munich, Germany
| | - Hongcheng Mai
- Institute for Tissue Engineering and Regenerative Medicine (iTERM), Helmholtz Zentrum München, 85764 Neuherberg, Germany; Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig Maximilian University of Munich (LMU), 81377 Munich, Germany
| | - Zhouyi Rong
- Institute for Tissue Engineering and Regenerative Medicine (iTERM), Helmholtz Zentrum München, 85764 Neuherberg, Germany; Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig Maximilian University of Munich (LMU), 81377 Munich, Germany
| | - Omelyan Trompak
- Institute of Neuropathology, University of Giessen, 35390 Giessen, Germany
| | - Alireza Ghasemigharagoz
- Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig Maximilian University of Munich (LMU), 81377 Munich, Germany
| | - Madita Alice Reimer
- Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig Maximilian University of Munich (LMU), 81377 Munich, Germany
| | - Angel M Cuesta
- Institute of Cell Biology and Neuroscience and Buchmann Institute for Molecular Life Sciences (BMLS), University of Frankfurt, 60323 Frankfurt, Germany
| | - Javier Coronel
- Department of Informatics, Technical University of Munich, 85748 Munich, Germany
| | - Irmela Jeremias
- Research Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum München, German Center for Environmental Health (HMGU), 81377 Munich, Germany; Department of Pediatrics, Dr. von Hauner Childrens Hospital, Ludwig Maximilian University of Munich (LMU), 81377 Munich, Germany; German Consortium for Translational Cancer Research (DKTK), Partnering Site Munich, 80336 Munich, Germany
| | - Dieter Saur
- Center for Translational Cancer Research (TranslaTUM), Klinikum rechts der Isar, Technical University of Munich, 81675 Munich, Germany; Division of Translational Cancer Research, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; German Cancer Consortium (DKTK), Partner Site Munich, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany
| | - Amparo Acker-Palmer
- Institute of Cell Biology and Neuroscience and Buchmann Institute for Molecular Life Sciences (BMLS), University of Frankfurt, 60323 Frankfurt, Germany
| | - Till Acker
- Institute of Neuropathology, University of Giessen, 35390 Giessen, Germany
| | - Boyan K Garvalov
- Institute of Neuropathology, University of Giessen, 35390 Giessen, Germany; Department of Microvascular Biology and Pathobiology, European Center for Angioscience (ECAS), Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany
| | - Bjoern Menze
- Department of Informatics, Technical University of Munich, 85748 Munich, Germany; Center for Translational Cancer Research (TranslaTUM), Klinikum rechts der Isar, Technical University of Munich, 81675 Munich, Germany; Munich School of Bioengineering, Technical University of Munich, 85748 Munich, Germany
| | - Reinhard Zeidler
- Research Unit Gene Vectors, Helmholtz Zentrum München, 81377 Munich, Germany; Department for Otorhinolaryngology, Klinikum der Universität München, Ludwig Maximilian University of Munich (LMU), 81377 Munich, Germany
| | - Ali Ertürk
- Institute for Tissue Engineering and Regenerative Medicine (iTERM), Helmholtz Zentrum München, 85764 Neuherberg, Germany; Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig Maximilian University of Munich (LMU), 81377 Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), 81377 Munich, Germany.
| |
Collapse
|
4
|
Sayad S, Ahmadi SAY, Moradi M, Nekouian R, Anbari K, Shahsavar F. A meta-analysis on diagnostic accuracy of serum HLA-G level in breast cancer. EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT 2020. [DOI: 10.1080/23808993.2020.1735936] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- Soheila Sayad
- Department of Breast Surgery, Firoozgar Clinical Research Development Center (FCRDC), Iran University of Medical Sciences, Tehran, Iran
| | - Seyyed Amir Yasin Ahmadi
- Student Research Committee, Iran University of Medical Sciences, Tehran, Iran
- Pediatric Growth and Development Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran
| | - Mohammad Moradi
- Department of Breast Surgery, Firoozgar Clinical Research Development Center (FCRDC), Iran University of Medical Sciences, Tehran, Iran
| | - Reza Nekouian
- Pediatric Growth and Development Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran
| | - Khatereh Anbari
- Social Determinants of Health Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran
| | - Farhad Shahsavar
- Department of Immunology, Lorestan University of Medical Sciences, Khorramabad, Iran
| |
Collapse
|
5
|
Gallo E, Kelil A, Bayliss PE, Jeganathan A, Egorova O, Ploder L, Adams JJ, Giblin P, Sidhu SS. In situ antibody phage display yields optimal inhibitors of integrin α11/β1. MAbs 2020; 12:1717265. [PMID: 31980006 PMCID: PMC6999838 DOI: 10.1080/19420862.2020.1717265] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2019] [Revised: 12/30/2019] [Accepted: 01/09/2020] [Indexed: 01/13/2023] Open
Abstract
Integrins are transmembrane multi-conformation receptors that mediate interactions with the extracellular matrix. In cancer, integrins influence metastasis, proliferation, and survival. Collagen-binding integrin-α11/β1, a marker of aggressive tumors that is involved in stroma-tumor crosstalk, may be an attractive target for anti-cancer therapeutic antibodies. We performed selections with phage-displayed synthetic antibody libraries for binding to either purified integrin-α11/β1 or in situ on live cells. The in-situ strategy yielded many diverse antibodies, and strikingly, most of these antibodies did not recognize purified integrin-α11/β1. Conversely, none of the antibodies selected for binding to purified integrin-α11/β1 were able to efficiently recognize native cell-surface antigen. Most importantly, only the in-situ selection yielded functional antibodies that were able to compete with collagen-I for binding to cell-surface integrin-α11/β1, and thus inhibited cell adhesion. In-depth characterization of a subset of in situ-derived clones as full-length immunoglobulins revealed high affinity cellular binding and inhibitory activities in the single-digit nanomolar range. Moreover, the antibodies showed high selectivity for integrin-α11/β1 with minimal cross-reactivity for close homologs. Taken together, our findings highlight the advantages of in-situ selections for generation of anti-integrin antibodies optimized for recognition and inhibition of native cell-surface proteins, and our work establishes general methods that could be extended to many other membrane proteins.
Collapse
Affiliation(s)
- Eugenio Gallo
- Department of Molecular Genetics, University of Toronto, Donnelly Centre, Toronto, Ontario, Canada
| | - Abdellali Kelil
- Department of Molecular Genetics, University of Toronto, Donnelly Centre, Toronto, Ontario, Canada
| | - Peter E. Bayliss
- Northern Biologics, Inc., Princess Margaret Cancer Research Tower, Toronto, Ontario, Canada
| | - Ajitha Jeganathan
- Northern Biologics, Inc., Princess Margaret Cancer Research Tower, Toronto, Ontario, Canada
| | - Olga Egorova
- Northern Biologics, Inc., Princess Margaret Cancer Research Tower, Toronto, Ontario, Canada
| | - Lynda Ploder
- Department of Molecular Genetics, University of Toronto, Donnelly Centre, Toronto, Ontario, Canada
| | - Jarret J. Adams
- Department of Molecular Genetics, University of Toronto, Donnelly Centre, Toronto, Ontario, Canada
| | - Patricia Giblin
- Northern Biologics, Inc., Princess Margaret Cancer Research Tower, Toronto, Ontario, Canada
| | - Sachdev S. Sidhu
- Department of Molecular Genetics, University of Toronto, Donnelly Centre, Toronto, Ontario, Canada
| |
Collapse
|
6
|
Abstract
Until recently, immunology was not a major focus of attention in the acute and critical care setting. With the evolution of immunotherapy, however-including the development of monoclonal antibodies, checkpoint inhibitors, and adoptive cellular therapies-an in-depth understanding of the immune system has become necessary to properly care for acutely ill patients. Lymphocytes (ie, T cells and B cells) play a major role in the daily functioning of the immune response. The interaction of these cells in protecting the body against infection and foreign substances is complicated and is the basis for many of the innovations in immunology and cancer treatment. This article explores basic immunology concepts, new drug categories, and adoptive cellular therapies that are at the forefront of cancer therapy.
Collapse
Affiliation(s)
- Nancy Munro
- Nancy Munro is Acute Care Nurse Practitioner, Critical Care Medicine Department, National Institutes of Health, 10 Center Dr, Bldg 10-CRC Room 3-3677, Bethesda, MD 20892
| |
Collapse
|
7
|
|
8
|
Rajagopal K, Chang D, Nayak P, Izadi S, Patapoff T, Zhang J, Kelley R, Sreedhara A. Trehalose Limits Fragment Antibody Aggregation and Influences Charge Variant Formation in Spray-Dried Formulations at Elevated Temperatures. Mol Pharm 2018; 16:349-358. [DOI: 10.1021/acs.molpharmaceut.8b01002] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Affiliation(s)
| | | | - Purnendu Nayak
- Eurofins Lancaster Laboratories, Lancaster, Pennsylvania 17605, United States
| | | | | | | | | | | |
Collapse
|
9
|
Bayer V, Amaya B, Baniewicz D, Callahan C, Marsh L, McCoy AS. Cancer Immunotherapy: An Evidence-Based Overview and Implications for Practice. Clin J Oncol Nurs 2017; 21:13-21. [PMID: 28315552 DOI: 10.1188/17.cjon.s2.13-21] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
BACKGROUND Significant research progress has been made in immunotherapies since the mid-1990s, and this rapid evolution necessitates evidence-based education on immunotherapies, their pathophysiology, and their toxicities to provide safe, effective care.
. OBJECTIVES The aim of this article is to provide an evidence-based overview, with implications for practice, of checkpoint inhibitors, monoclonal antibodies, oncolytic viral therapies, and chimeric antigen receptor T-cell therapies.
. METHODS Each immunotherapy category is presented according to the pathophysiology of its immune modulation, the classes of agents within each category, evidence-based toxicities associated with each class, and implications for practice.
. FINDINGS Immunotherapies vary in their pathophysiology and offer potential to be highly effective for the management of a wide array of cancer types. Understanding the unique pathophysiology and toxicities is necessary to assess, manage, and provide safe, effective patient-focused care.
Collapse
Affiliation(s)
| | | | | | | | - Lisa Marsh
- University of Texas MD Anderson Cancer Center
| | | |
Collapse
|
10
|
Kasturirangan S, Rainey GJ, Xu L, Wang X, Portnoff A, Chen T, Fazenbaker C, Zhong H, Bee J, Zeng Z, Jenne C, Wu H, Gao C. Targeted Fcγ Receptor (FcγR)-mediated Clearance by a Biparatopic Bispecific Antibody. J Biol Chem 2017; 292:4361-4370. [PMID: 28100773 PMCID: PMC5354496 DOI: 10.1074/jbc.m116.770628] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2016] [Revised: 01/09/2017] [Indexed: 11/14/2022] Open
Abstract
Soluble ligands have commonly been targeted by antibody therapeutics for cancers and other diseases. Although monoclonal antibodies targeting such ligands can block their interactions with their cognate receptors, they can also significantly increase the half-life of their ligands by FcRn-mediated antibody recycling, thereby evading ligand renal clearance and requiring increasingly high antibody doses to neutralize the increasing pool of target. To overcome this issue, we generated a bispecific/biparatopic antibody (BiSAb) that targets two different epitopes on IL-6 to block IL-6-mediated signaling. The BiSAb formed large immune complexes with IL-6 that can bind Fcγ receptors on phagocytic cells and are rapidly internalized. In addition, rapid clearance of the BiSAb·IL-6 complex was observed in mice while the parental antibodies prolonged the serum half-life of IL-6. Intravital imaging of the liver in mice confirmed that the rapid clearance of these large immune complexes was associated with Fcγ receptor-dependent binding to Kupffer cells in the liver. The approach described here provides a general strategy for therapeutic antibodies with the ability to not only neutralize but also actively drive clearance of their soluble antigens.
Collapse
Affiliation(s)
| | - G Jonah Rainey
- From the Departments of Antibody Discovery and Protein Engineering
| | - Linda Xu
- From the Departments of Antibody Discovery and Protein Engineering
| | - Xinwei Wang
- From the Departments of Antibody Discovery and Protein Engineering
| | - Alyse Portnoff
- From the Departments of Antibody Discovery and Protein Engineering
| | | | | | | | - Jared Bee
- Analytical Biotechnology, Medimmune LLC, Gaithersburg, Maryland 20878 and
| | - Zhutian Zeng
- the Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, Alberta T2N 4N1, Canada
| | - Craig Jenne
- the Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, Alberta T2N 4N1, Canada
| | - Herren Wu
- From the Departments of Antibody Discovery and Protein Engineering
| | - Changshou Gao
- From the Departments of Antibody Discovery and Protein Engineering,
| |
Collapse
|
11
|
Ouisse LH, Gautreau-Rolland L, Devilder MC, Osborn M, Moyon M, Visentin J, Halary F, Bruggemann M, Buelow R, Anegon I, Saulquin X. Antigen-specific single B cell sorting and expression-cloning from immunoglobulin humanized rats: a rapid and versatile method for the generation of high affinity and discriminative human monoclonal antibodies. BMC Biotechnol 2017; 17:3. [PMID: 28081707 PMCID: PMC5234254 DOI: 10.1186/s12896-016-0322-5] [Citation(s) in RCA: 38] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2016] [Accepted: 12/07/2016] [Indexed: 01/03/2023] Open
Abstract
Background There is an ever-increasing need of monoclonal antibodies (mAbs) for biomedical applications and fully human binders are particularly desirable due to their reduced immunogenicity in patients. We have applied a strategy for the isolation of antigen-specific B cells using tetramerized proteins and single-cell sorting followed by reconstruction of human mAbs by RT-PCR and expression cloning. Results This strategy, using human peripheral blood B cells, enabled the production of low affinity human mAbs against major histocompatibility complex molecules loaded with peptides (pMHC). We then implemented this technology using human immunoglobulin transgenic rats, which after immunization with an antigen of interest express high affinity-matured antibodies with human idiotypes. Using rapid immunization, followed by tetramer-based B-cell sorting and expression cloning, we generated several fully humanized mAbs with strong affinities, which could discriminate between highly homologous proteins (eg. different pMHC complexes). Conclusions Therefore, we describe a versatile and more effective approach as compared to hybridoma generation or phage or yeast display technologies for the generation of highly specific and discriminative fully human mAbs that could be useful both for basic research and immunotherapeutic purposes. Electronic supplementary material The online version of this article (doi:10.1186/s12896-016-0322-5) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Laure-Hélène Ouisse
- INSERM Center for Research in Transplantation and Immunology (CRTI) U1064; Université de Nantes; Centre Hospitalier Universitaire de Nantes Institut de Transplantation Urologie Néphrologie (ITUN), Nantes, F44000, France.,Transgenesis Rat ImmunoPhenomic Platform Structure Fédérative de Recherche François Bonamy Centre National de Recherche Scientifique UMS3556, Nantes, F44093, France
| | - Laetitia Gautreau-Rolland
- CRCNA UMR S892 INSERM 6299 CNRS Université de Nantes; Université de Nantes Faculté des Sciences et Techniques, Nantes, F44093, France
| | - Marie-Claire Devilder
- CRCNA UMR S892 INSERM 6299 CNRS Université de Nantes; Centre Hospitalier Universitaire de Nantes, Nantes, F44093, France
| | - Michael Osborn
- Recombinant Antibody Technology Babraham Research Campus, Cambridge, CB22 3AT, UK
| | - Melinda Moyon
- CRCNA UMR S892 INSERM 6299 CNRS Université de Nantes; Centre Hospitalier Universitaire de Nantes, Nantes, F44093, France
| | - Jonathan Visentin
- Centre Hospitalier Universitaire de Bordeaux Laboratoire d'Immunologie et Immunogénétique Hôpital Pellegrin Bordeaux, Bordeaux, F33076, France.,Université de Bordeaux UMR CNRS 5164 , Talence, F33400, France
| | - Frank Halary
- INSERM Center for Research in Transplantation and Immunology (CRTI) U1064; Université de Nantes; Centre Hospitalier Universitaire de Nantes Institut de Transplantation Urologie Néphrologie (ITUN), Nantes, F44000, France
| | - Marianne Bruggemann
- Recombinant Antibody Technology Babraham Research Campus, Cambridge, CB22 3AT, UK
| | | | - Ignacio Anegon
- INSERM Center for Research in Transplantation and Immunology (CRTI) U1064; Université de Nantes; Centre Hospitalier Universitaire de Nantes Institut de Transplantation Urologie Néphrologie (ITUN), Nantes, F44000, France. .,Transgenesis Rat ImmunoPhenomic Platform Structure Fédérative de Recherche François Bonamy Centre National de Recherche Scientifique UMS3556, Nantes, F44093, France.
| | - Xavier Saulquin
- CRCNA UMR S892 INSERM 6299 CNRS Université de Nantes; Université de Nantes Faculté des Sciences et Techniques, Nantes, F44093, France.
| |
Collapse
|
12
|
Development of a robust reporter-based assay for the bioactivity determination of anti-VEGF therapeutic antibodies. J Pharm Biomed Anal 2016; 125:212-8. [DOI: 10.1016/j.jpba.2016.03.042] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2016] [Revised: 03/18/2016] [Accepted: 03/21/2016] [Indexed: 12/21/2022]
|
13
|
Beyond adjuvants: Antagonizing inflammation to enhance vaccine immunity. Vaccine 2016; 33 Suppl 2:B55-9. [PMID: 26022570 DOI: 10.1016/j.vaccine.2015.03.058] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2015] [Accepted: 03/19/2015] [Indexed: 11/20/2022]
Abstract
Since the development of the first vaccine over 200 years ago, vaccines have saved millions of lives and have become the most cost-effective modern medical intervention. However, over 70 years ago, Freund recognized that the effectiveness of the vaccine-induced immune responses could be vastly improved via the co-delivery of inflammation-induced agents, giving birth to the adjuvant field. Since the first description of adjuvants, revolutionary discoveries, including the discovery of dendritic cells and pattern recognition receptors, that drive remarkably different biological profiles, have opened the landscape of opportunities for the development of novel adjuvants able to trigger a remarkably diverse inflammatory profiles, thereby qualitatively and quantitatively skewing adaptive immunity in a tailored manner against target pathogens. However, mounting data point to a critical role for pre-existing inflammation as a predictor of vaccine responsiveness. Thus, in this review we will discuss novel opportunities by which pre-existing inflammation may be modulated, skewed, or tuned via next-generation vaccine approaches to enhanced vaccine-induced immunity in the elderly, immunocompromised, or subjects with chronic diseases.
Collapse
|
14
|
Kheddo P, Golovanov AP, Mellody KT, Uddin S, van der Walle CF, Dearman RJ. The effects of arginine glutamate, a promising excipient for protein formulation, on cell viability: Comparisons with NaCl. Toxicol In Vitro 2016; 33:88-98. [PMID: 26873863 PMCID: PMC4837223 DOI: 10.1016/j.tiv.2016.02.002] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2015] [Revised: 01/28/2016] [Accepted: 02/06/2016] [Indexed: 12/31/2022]
Abstract
The effects of an equimolar mixture of l-arginine and l-glutamate (Arg·Glu) on cell viability and cellular stress using in vitro cell culture systems are examined with reference to NaCl, in the context of monoclonal antibody formulation. Cells relevant to subcutaneous administration were selected: the human monocyte cell line THP-1, grown as a single cell suspension, and adherent human primary fibroblasts. For THP-1 cells, the mechanism of cell death caused by relatively high salt concentrations was investigated and effects on cell activation/stress assessed as a function of changes in membrane marker and cytokine (interleukin-8) expression. These studies demonstrated that Arg·Glu does not have any further detrimental effects on THP-1 viability in comparison to NaCl at equivalent osmolalities, and that both salts at higher concentrations cause cell death by apoptosis; there was no significant effect on measures of THP-1 cellular stress/activation. For adherent fibroblasts, both salts caused significant toxicity at ~400 mOsm/kg, although Arg·Glu caused a more precipitous subsequent decline in viability than did NaCl. These data indicate that Arg·Glu is of equivalent toxicity to NaCl and that the mechanism of toxicity is such that cell death is unlikely to trigger inflammation upon subcutaneous injection in vivo.
Collapse
Affiliation(s)
- Priscilla Kheddo
- Manchester Institute of Biotechnology, University of Manchester, Manchester M1 7DN, UK; Faculty of Life Sciences, University of Manchester, Manchester M13 9PL, UK
| | - Alexander P Golovanov
- Manchester Institute of Biotechnology, University of Manchester, Manchester M1 7DN, UK; Faculty of Life Sciences, University of Manchester, Manchester M13 9PL, UK
| | - Kieran T Mellody
- Faculty of Life Sciences, University of Manchester, Manchester M13 9PL, UK
| | - Shahid Uddin
- MedImmune Ltd, Granta Park, Cambridge CB21 6GH, UK
| | | | - Rebecca J Dearman
- Faculty of Life Sciences, University of Manchester, Manchester M13 9PL, UK.
| |
Collapse
|
15
|
Cutler P, Voshol H. Proteomics in pharmaceutical research and development. Proteomics Clin Appl 2015; 9:643-50. [PMID: 25763573 DOI: 10.1002/prca.201400181] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2014] [Revised: 02/10/2015] [Accepted: 03/09/2015] [Indexed: 01/07/2023]
Abstract
In the 20 years since its inception, the evolution of proteomics in pharmaceutical industry has mirrored the developments within academia and indeed other industries. From initial enthusiasm and subsequent disappointment in global protein expression profiling, pharma research saw the biggest impact when relating to more focused approaches, such as those exploring the interaction between proteins and drugs. Nowadays, proteomics technologies have been integrated in many areas of pharmaceutical R&D, ranging from the analysis of therapeutic proteins to the monitoring of clinical trials. Here, we review the development of proteomics in the drug discovery process, placing it in a historical context as well as reviewing the current status in light of the contributions to this special issue, which reflect some of the diverse demands of the drug and biomarker pipelines.
Collapse
Affiliation(s)
- Paul Cutler
- Translational Technologies and Bioinformatics, Pharmaceutical Sciences, Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche AG, Basel, Switzerland
| | - Hans Voshol
- Novartis Institutes for BioMedical Research, Analytical Sciences and Imaging, Basel, Switzerland
| |
Collapse
|
16
|
Morar-Mitrica S, Puri M, Beumer Sassi A, Fuller J, Hu P, Crotts G, Nesta D. Development of a stable low-dose aglycosylated antibody formulation to minimize protein loss during intravenous administration. MAbs 2015; 7:792-803. [PMID: 26073995 PMCID: PMC4622870 DOI: 10.1080/19420862.2015.1046664] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2015] [Revised: 04/21/2015] [Accepted: 04/22/2015] [Indexed: 10/23/2022] Open
Abstract
The physical and chemical integrity of a biopharmaceutical must be maintained not only during long-term storage but also during administration. Specifically for the intravenous (i.v.) delivery of a protein drug, loss of stability can occur when the protein formulation is compounded with i.v. bag diluents, thus modifying the original composition of the drug product. Here we present the challenges associated with the delivery of a low-dose, highly potent monoclonal antibody (mAb) via the i.v. route. Through parallel in-use stability studies and conventional formulation development, a drug product was developed in which adsorptive losses and critical oxidative degradation pathways were effectively controlled. This development approach enabled the i.v. administration of clinical doses in the range of 0.1 to 0.5 mg total protein, while ensuring liquid drug product storage stability under refrigerated conditions.
Collapse
Key Words
- CD3, cluster of differentiation 3
- CMC, critical micelle concentration
- Cys, cysteine
- DSC, differential scanning calorimetry
- EDTA, edetate disodium
- Glut, glutathione
- HPLC, high performance liquid chromatography
- M, methionine residues
- MS, mass spectrometry
- MTG, monothioglycerol
- Met, methionine
- PES, polyethersulfone
- PO, polyolefin
- PS80, polysorbate 80
- PVC, polyvinylchloride
- SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis
- administration
- adsorption
- antioxidant
- biopharmaceutical
- cIEF, capillary isoelectric focusing
- dilution
- i.v., intravenous
- infusion
- intravenous
- low concentration
- low dose
- mAb, monoclonal antibody
- monoclonal antibody
- oxidation
- stability
- surfactant
Collapse
Affiliation(s)
- Sorina Morar-Mitrica
- Biopharmaceutical Product Sciences; GlaxoSmithKline R&D; King of Prussia, PA, USA
| | - Manasi Puri
- Biopharmaceutical Product Sciences; GlaxoSmithKline R&D; King of Prussia, PA, USA
| | | | - Joshua Fuller
- Bioanalytical Sciences; GlaxoSmithKline R&D; King of Prussia, PA, USA
| | - Ping Hu
- Analytical Development; Janssen R&D, LLC; Malvern, PA, US
| | - George Crotts
- Biopharmaceutical Product Sciences; GlaxoSmithKline R&D; King of Prussia, PA, USA
| | - Douglas Nesta
- Biopharmaceutical Product Sciences; GlaxoSmithKline R&D; King of Prussia, PA, USA
| |
Collapse
|
17
|
|